BST | Jotup

Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO

Retrieved on:

Venerdì, Maggio 31, 2024

At the February 7, 2024, data cut-off date, the majority of ongoing responders showed durable responses.

Key Points:

At the February 7, 2024, data cut-off date, the majority of ongoing responders showed durable responses.
Patients who experienced B-cell recovery had a 1.7 fold increased risk of relapse or compared with patients without B-cell recovery.
In conclusion these data support the potential of a long-term plateau of survival outcomes in patients receiving obe-cel.
A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.

Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024

Retrieved on:

Venerdì, Maggio 31, 2024

BST, Research fellow, EDT, Therapy, Webcast, Participation, SIX, DSM-IV codes

Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it will issue its Q1 2024 Financial Results on June 6, 2024.

Key Points:

Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it will issue its Q1 2024 Financial Results on June 6, 2024.
Participants are required to register in advance of the conference using the link provided below.
Upon registering, each participant will be provided with Participant Dial-in numbers, and a unique Personal PIN.
In the 10 minutes prior to the call’s start time, participants will need to use the conference access information provided in the e-mail received at the point of registering.

Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

Retrieved on:

Giovedì, Maggio 30, 2024

BST, Conference, Fireside, Webcast, Fireside chats

LONDON, May 30, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 11:00am ET / 04:00pm BST.

Key Points:

LONDON, May 30, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 11:00am ET / 04:00pm BST.
A live audio webcast of the presentation can be accessed through the Investors section of the Company’s website at www.mereobiopharma.com/investors .
An archived replay of the webcast will be available on the Company’s website for two weeks following the live event.

Liberty Global to Present at the Bank of America C-Suite TMT Conference

Retrieved on:

Giovedì, Maggio 30, 2024

Technology, Mobile, Wireless, Finance, 5G, Carriers and Services, Telecommunications, Professional Services, Audio, Video, Internet, BST, Liberty Global, Conference, Bank

Liberty Global Ltd. (“Liberty Global”) (NASDAQ: LBTYA, LBTYB and LBTYK) will be presenting at the Bank of America C-Suite TMT Conference on Tuesday, June 11, 2024, at 10:35 am BST.

Key Points:

Liberty Global Ltd. (“Liberty Global”) (NASDAQ: LBTYA, LBTYB and LBTYK) will be presenting at the Bank of America C-Suite TMT Conference on Tuesday, June 11, 2024, at 10:35 am BST.
Liberty Global may make observations concerning its historical operating performance and outlook.
The presentation will be webcast live at www.libertyglobal.com .
We intend to archive the webcast under the Investor Relations section of our website for approximately 30 days.

Exscientia to Present at Upcoming Investor Conferences in June

Retrieved on:

Giovedì, Maggio 30, 2024

Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Research, Software, Artificial Intelligence, Science, Clinical Trials, BST, Disruptive innovation, EDT, Goldman Sachs, Conference, Barclays

Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in the following upcoming investor conferences in June:

Key Points:

Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in the following upcoming investor conferences in June:
Barclays Digital and Disruptive Technology Conference.
Panel on Tuesday, June 11, 2024 at 9:45 a.m. BST in London, England
Goldman Sachs 45th Annual Global Healthcare Conference.
Fireside chat on Tuesday, June 11, 2024 at 3:20 p.m. EDT (8:20 p.m. BST) in Miami, Florida
Live webcasts of the Barclays and Goldman Sachs events will be available on the Company’s website, under the “Investors & Media” section at www.investors.exscientia.ai .
Archived replays of the webcasts will be available for approximately 30 days following the presentation.

HUB Cyber Security and BlackSwan to Jointly Showcase Advanced Secured Data Fabric Solution at Money 20/20 Event

Retrieved on:

Mercoledì, Maggio 29, 2024

Money, Confidentiality, Organization, BST, HUB, Government, Data management, TEL, SDF, IBN

Together, the strategic partners will demonstrate the cutting-edge Secured Data Fabric (SDF) solution, designed to facilitate secure access to data across multiple sectors.

Key Points:

Together, the strategic partners will demonstrate the cutting-edge Secured Data Fabric (SDF) solution, designed to facilitate secure access to data across multiple sectors.
The SDF solution is specifically engineered to ensure that sensitive information can be accessed in a controlled and secure manner.
Noah Hershcoviz, CEO of HUB Cyber Security Ltd., commented, “We are excited to present our Secured Data Fabric solution at Money 20/20 with our partner, BST.
This technology offers advanced protection and control over sensitive information, ensuring data security and integrity as industries rely more on data for their operations.”
For further information or inquiries, please contact: [email protected]

Notice of Iceland Capital Markets Day

Retrieved on:

Martedì, Maggio 28, 2024

BST, AIM, Gold, Nasdaq Iceland, EDT, Capital market

TORONTO, ONTARIO – May 28, 2024 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mine development company with a substantial land package of gold and strategic mineral assets in Southern Greenland, announces that it will hold a Capital Markets Day on Thursday, June 13th, from 14:00 pm to 16:00 pm GMT (10:00 am to 12:00 pm EDT and 15:00 pm to 17:00 pm BST).

Key Points:

TORONTO, ONTARIO – May 28, 2024 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mine development company with a substantial land package of gold and strategic mineral assets in Southern Greenland, announces that it will hold a Capital Markets Day on Thursday, June 13th, from 14:00 pm to 16:00 pm GMT (10:00 am to 12:00 pm EDT and 15:00 pm to 17:00 pm BST).
The event will be held at Landsbankinn‘s headquarters at Reykjastræti 6 and the doors will open at 13:30 pm, with a reception will be held after the event.
Please register below to attend in person.
The event will also be broadcast live to enable remote access and will be held in English.

Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness

Retrieved on:

Mercoledì, Maggio 22, 2024

MONTREAL and CHARLOTTE, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced it will partner with Arrhythmia Alliance to raise awareness of supraventricular tachycardia (SVT).

Key Points:

MONTREAL and CHARLOTTE, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced it will partner with Arrhythmia Alliance to raise awareness of supraventricular tachycardia (SVT).
SVT Awareness Day will be held on Wednesday June 5, 2024, during World Heart Rhythm Week (June 4-10), to raise awareness of SVT, a type of arrhythmia or rapid heart rhythm that leaves people with palpitations (“racing heart rate”), breathlessness, and anxiety.
“We are honored to partner with the Arrhythmia Alliance on educational initiatives for SVT Awareness Day.
For additional information on SVT, visit SVT Heart to Heart provided by Milestone Pharmaceuticals.

At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Demonstrates Superiority in Phase i Clinical Trial in Overweight and Obese People With Type 2 Diabetes

Retrieved on:

Lunedì, Maggio 20, 2024

With no concentrated (>200 U/mL), rapid acting insulins on the market, AT278 has potential to be the first, and only, insulin available to the growing number of patients with high daily insulin requirements.

Key Points:

With no concentrated (>200 U/mL), rapid acting insulins on the market, AT278 has potential to be the first, and only, insulin available to the growing number of patients with high daily insulin requirements.
They further add to the positive results from our previous clinical study in Type 1 diabetic patients, where superiority was also demonstrated.
AT278 has the potential to be the only highly concentrated, ultra-rapid acting insulin to enable the next generation of miniaturised, longer wear insulin pumps.
Pharmacokinetics and Pharmacodynamics of a Novel U500 Insulin Aspart Formulation: A Randomized, Double-Blind, Crossover Study in People With Type 1 Diabetes Care 2023;46(4):757–764: https://doi.org/10.2337/dc22-1054

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024

Retrieved on:

Mercoledì, Maggio 15, 2024

Insurance, PIN, Medicare, GWAC, Kidney disease, Food, BST, FDA, EDT, Government, Telephone, Sale, Total, De novo, Research, Food and Drug Administration, Pharmaceutical industry

LONDON and NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal third quarter ended March 31, 2024.

Key Points:

LONDON and NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal third quarter ended March 31, 2024.
Cost of revenue for the three months ended March 31, 2024 and 2023, was $0.6 million.
Operating expenses for the three months ended March 31, 2024 were $6.5 million, compared to $11.0 million during the prior year period.
Operating cash burn in the fiscal third quarter was $4.9 million, nearly 40% lower than the fiscal second quarter and a 50% reduction from the year ago period.